Danish pharmaceutical company Genmab has released new phase 1b/2 data demonstrating strong responses for epcoritamab, both as a monotherapy and in combination, in patients with Richter's transformation.
Monotherapy with epcoritamab yielded high rates of complete responses and a median overall survival of 27.5 months in the first-line setting.
Early results from the combination arms also indicate high activity, with response rates of up to 82 percent in the epcoritamab-lenalidomide group and 77 percent in the epcoritamab-R-CHOP group.
The safety profile is described as consistent with previous studies, although several serious adverse events were reported.
“The results from these studies highlight the potential of epcoritamab as a monotherapy and in combination for patients with Richter's transformation, a rare and often fatal progression of chronic lymphocytic leukemia into an aggressive lymphoma, most commonly diffuse large B-cell lymphoma,” said Dr. Judith Klimovsky, Executive Vice President and Chief Development Officer at Genmab.
“We are committed to investigating epcoritamab as a potential foundational therapy for a range of B-cell malignancies, both as an initial treatment and in later lines of therapy,” she added.
